A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GENESTRETI, Paulo Rizzo e BARACIOLI, Luciano Moreira e NICOLAU, Jose Carlos. Evento coronariano agudo no paciente diabético. Diabetes e doença cardiovaculares. Tradução . Rio de Janeiro: Atheneu, 2023. . . Acesso em: 10 out. 2024.
APA
Genestreti, P. R., Baracioli, L. M., & Nicolau, J. C. (2023). Evento coronariano agudo no paciente diabético. In Diabetes e doença cardiovaculares. Rio de Janeiro: Atheneu.
NLM
Genestreti PR, Baracioli LM, Nicolau JC. Evento coronariano agudo no paciente diabético. In: Diabetes e doença cardiovaculares. Rio de Janeiro: Atheneu; 2023. [citado 2024 out. 10 ]
Vancouver
Genestreti PR, Baracioli LM, Nicolau JC. Evento coronariano agudo no paciente diabético. In: Diabetes e doença cardiovaculares. Rio de Janeiro: Atheneu; 2023. [citado 2024 out. 10 ]
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M. et al. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, v. 145, n. 21, p. 1581-1591, 2022Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.121.058103. Acesso em: 10 out. 2024.
APA
Furtado, R. H. M., Raz, I., Goodrich, E. L., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2022). Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial. Circulation, 145( 21), 1581-1591. doi:10.1161/CIRCULATIONAHA.121.058103
NLM
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
Vancouver
Furtado RHM, Raz I, Goodrich EL, Murphy SA, Bhatt DL, Leiter LA, Mcguire DK, Wilding JPH, Aylward P, Dalby AJ, Nicolau JC. Efficacy and Safety of Dapagliflozin in Type 2 Diabetes According to Baseline Blood Pressure: Observations From DECLARE-TIMI 58 Trial [Internet]. Circulation. 2022 ; 145( 21): 1581-1591.[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.121.058103
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
PETRIE, Mark C et al. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, v. 323, n. 14, p. 1353-1368, 2020Tradução . . Disponível em: https://doi.org/10.1001/jama.2020.1906. Acesso em: 10 out. 2024.
APA
Petrie, M. C., Verma, S., Docherty, K. F., Inzucchi, S. E., Anand, I., Belohlavek, J., et al. (2020). Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes. Jama-journal of the american medical association, 323( 14), 1353-1368. doi:10.1001/jama.2020.1906
NLM
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 out. 10 ] Available from: https://doi.org/10.1001/jama.2020.1906
Vancouver
Petrie MC, Verma S, Docherty KF, Inzucchi SE, Anand I, Belohlavek J, Boehm M, Chiang C-E, Chopra VK, Nicolau JC. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes [Internet]. Jama-journal of the american medical association. 2020 ; 323( 14): 1353-1368.[citado 2024 out. 10 ] Available from: https://doi.org/10.1001/jama.2020.1906
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FRANCHI, Francesco et al. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, v. 8, n. 6, 2019Tradução . . Disponível em: https://doi.org/10.1161/JAHA.118.011139. Acesso em: 10 out. 2024.
APA
Franchi, F., James, S. K., Lakic, T. G., Budaj, A. J., Cornel, J. H., Katus, H. A., et al. (2019). Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial. Journal of the american heart association, 8( 6). doi:10.1161/JAHA.118.011139
NLM
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/JAHA.118.011139
Vancouver
Franchi F, James SK, Lakic TG, Budaj AJ, Cornel JH, Katus HA, Keltai M, Kontny F, Lewis BS, Nicolau JC. Impact of diabetes mellitus and chronic kidney disease on cardiovascular outcomes and platelet P2Y(12) receptor antagonist effects in patients with acute coronary syndromes: insights from the PLATO trial [Internet]. Journal of the american heart association. 2019 ; 8( 6):[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/JAHA.118.011139
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
RAY, Kausik K et al. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, v. 7, n. 8, p. 618-628, 2019Tradução . . Disponível em: https://doi.org/10.1016/S2213-8587(19)30158-5. Acesso em: 10 out. 2024.
APA
Ray, K. K., Colhoun, H. M., Szarek, M., Baccara-dinet, M., Bhatt, D. L., Bittner, V. A., et al. (2019). Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. Lancet diabetes & endocrinology, 7( 8), 618-628. doi:10.1016/S2213-8587(19)30158-5
NLM
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
Vancouver
Ray KK, Colhoun HM, Szarek M, Baccara-dinet M, Bhatt DL, Bittner VA, Budaj AJ, Diaz R, Goodman SG, Nicolau JC. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial [Internet]. Lancet diabetes & endocrinology. 2019 ; 7( 8): 618-628.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/S2213-8587(19)30158-5
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
STEG, P. Gabriel et al. Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, v. 381, n. 14, p. 1309-1320, 2019Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa1908077. Acesso em: 10 out. 2024.
APA
Steg, P. G., Bhatt, D. L., Simon, T., Fox, K., Mehta, S. R., Harrington, R. A., et al. (2019). Ticagrelor in patients with stable coronary disease and diabetes. New england journal of medicine, 381( 14), 1309-1320. doi:10.1056/NEJMoa1908077
NLM
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 out. 10 ] Available from: https://doi.org/10.1056/NEJMoa1908077
Vancouver
Steg PG, Bhatt DL, Simon T, Fox K, Mehta SR, Harrington RA, Held C, Andersson M, Himmelmann A, Nicolau JC. Ticagrelor in patients with stable coronary disease and diabetes [Internet]. New england journal of medicine. 2019 ; 381( 14): 1309-1320.[citado 2024 out. 10 ] Available from: https://doi.org/10.1056/NEJMoa1908077
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GODOY, Lucas C et al. Urgent revascularization strategies in patients with diabetes mellitus and acute coronary syndrome. Canadian journal of cardiology, v. 35, n. 8, p. 993-1001, 2019Tradução . . Disponível em: https://doi.org/10.1016/j.cjca.2019.03.010. Acesso em: 10 out. 2024.
APA
Godoy, L. C., Lawler, P. R., Farkouh, M. E., Hersen, B., Nicolau, J. C., & Rao, V. (2019). Urgent revascularization strategies in patients with diabetes mellitus and acute coronary syndrome. Canadian journal of cardiology, 35( 8), 993-1001. doi:10.1016/j.cjca.2019.03.010
NLM
Godoy LC, Lawler PR, Farkouh ME, Hersen B, Nicolau JC, Rao V. Urgent revascularization strategies in patients with diabetes mellitus and acute coronary syndrome [Internet]. Canadian journal of cardiology. 2019 ; 35( 8): 993-1001.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.cjca.2019.03.010
Vancouver
Godoy LC, Lawler PR, Farkouh ME, Hersen B, Nicolau JC, Rao V. Urgent revascularization strategies in patients with diabetes mellitus and acute coronary syndrome [Internet]. Canadian journal of cardiology. 2019 ; 35( 8): 993-1001.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.cjca.2019.03.010
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BHATT, Deepak L et al. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, v. 42, n. 5, p. 498-505, 2019Tradução . . Disponível em: https://doi.org/10.1002/clc.23164. Acesso em: 10 out. 2024.
APA
Bhatt, D. L., Fox, K., Harrington, R. A., Leiter, L. A., Mehta, S. R., Simon, T., et al. (2019). Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study. Clinical cardiology, 42( 5), 498-505. doi:10.1002/clc.23164
NLM
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 out. 10 ] Available from: https://doi.org/10.1002/clc.23164
Vancouver
Bhatt DL, Fox K, Harrington RA, Leiter LA, Mehta SR, Simon T, Andersson M, Himmelmann A, Ridderstrale W, Nicolau JC. Rationale, design and baseline characteristics of the effect of ticagrelor on health outcomes in diabetes mellitus patients Intervention study [Internet]. Clinical cardiology. 2019 ; 42( 5): 498-505.[citado 2024 out. 10 ] Available from: https://doi.org/10.1002/clc.23164
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
EVERETT, Brendan M. et al. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, v. 71, n. 21, p. 2392-2401, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.03.002. Acesso em: 10 out. 2024.
APA
Everett, B. M., Nicolau, J. C., DONATH, M. Y., PRADHAN, A. D., THUREN, T., PAIS, P., et al. (2018). Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes. Journal of the american college of cardiology, 71( 21), 2392-2401. doi:10.1016/j.jacc.2018.03.002
NLM
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
Vancouver
Everett BM, Nicolau JC, DONATH MY, PRADHAN AD, THUREN T, PAIS P, GLYNN RJ, LIBBY P, RIDKER PM. Anti-Inflammatory Therapy With Canakinumab for the Prevention and Management of Diabetes [Internet]. Journal of the american college of cardiology. 2018 ; 71( 21): 2392-2401.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.jacc.2018.03.002
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 10 out. 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 out. 10 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIANCO, Henrique T. et al. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. International Journal of Cardiology. Amsterdan: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.ijcard.2014.07.251. Acesso em: 10 out. 2024. , 2014
APA
Bianco, H. T., Izar, M. C., Póvoa, R. M., Bombig, M. T., Fonseca, H. A., Helfenstein, T., et al. (2014). Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. International Journal of Cardiology. Amsterdan: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.ijcard.2014.07.251
NLM
Bianco HT, Izar MC, Póvoa RM, Bombig MT, Fonseca HA, Helfenstein T, Ferreira CE, Nicolau JC, Afiune Neto A, Feio CM, Cerci MS, Fonseca FA. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes [Internet]. International Journal of Cardiology. 2014 ; 176 1170-1172.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.ijcard.2014.07.251
Vancouver
Bianco HT, Izar MC, Póvoa RM, Bombig MT, Fonseca HA, Helfenstein T, Ferreira CE, Nicolau JC, Afiune Neto A, Feio CM, Cerci MS, Fonseca FA. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes [Internet]. International Journal of Cardiology. 2014 ; 176 1170-1172.[citado 2024 out. 10 ] Available from: https://doi.org/10.1016/j.ijcard.2014.07.251
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, José Carlos et al. Pacientes Diabéticos com Síndromes Coronárias Agudas têm um Limiar Maior para a Dor Isquêmica?. Arquivos Brasileiros de Cardiologia, v. 103, n. 3, p. 183-191, 2014Tradução . . Disponível em: http://www.scielo.br/pdf/abc/v103n3/pt_0066-782X-abc-20140106.pdf. Acesso em: 10 out. 2024.
APA
Nicolau, J. C., Barbosa, C. J. D. G., Franci, A., Baracioli, L. M., Franken, M., Lima, F. G., et al. (2014). Pacientes Diabéticos com Síndromes Coronárias Agudas têm um Limiar Maior para a Dor Isquêmica? Arquivos Brasileiros de Cardiologia, 103( 3), 183-191. Recuperado de http://www.scielo.br/pdf/abc/v103n3/pt_0066-782X-abc-20140106.pdf
NLM
Nicolau JC, Barbosa CJDG, Franci A, Baracioli LM, Franken M, Lima FG, Giraldez RR, Kalil Filho R, Ramires JAF, Giugliano RP. Pacientes Diabéticos com Síndromes Coronárias Agudas têm um Limiar Maior para a Dor Isquêmica? [Internet]. Arquivos Brasileiros de Cardiologia. 2014 ; 103( 3): 183-191.[citado 2024 out. 10 ] Available from: http://www.scielo.br/pdf/abc/v103n3/pt_0066-782X-abc-20140106.pdf
Vancouver
Nicolau JC, Barbosa CJDG, Franci A, Baracioli LM, Franken M, Lima FG, Giraldez RR, Kalil Filho R, Ramires JAF, Giugliano RP. Pacientes Diabéticos com Síndromes Coronárias Agudas têm um Limiar Maior para a Dor Isquêmica? [Internet]. Arquivos Brasileiros de Cardiologia. 2014 ; 103( 3): 183-191.[citado 2024 out. 10 ] Available from: http://www.scielo.br/pdf/abc/v103n3/pt_0066-782X-abc-20140106.pdf
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. The prognostic value of diabetes and of acute hyperglycemia is different during the in-hospital and chronic phases after myicardial infarction. Journal of the American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271027&_user=5674931&_pii=S0735109711610413&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2011-04-05&wchp=dGLbVlk-zSkWb&md5=c12e778a15601d89389d60fa28e84374/1-s2.0-S0735109711610413-main.pdf. Acesso em: 10 out. 2024. , 2011
APA
Nicolau, J. C., Lima, F. G., Franken, M., Serrano Junior, C. V., Giraldez, R. R., Baracioli, L. M., et al. (2011). The prognostic value of diabetes and of acute hyperglycemia is different during the in-hospital and chronic phases after myicardial infarction. Journal of the American College of Cardiology. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271027&_user=5674931&_pii=S0735109711610413&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2011-04-05&wchp=dGLbVlk-zSkWb&md5=c12e778a15601d89389d60fa28e84374/1-s2.0-S0735109711610413-main.pdf
NLM
Nicolau JC, Lima FG, Franken M, Serrano Junior CV, Giraldez RR, Baracioli LM, Ganem F, Fernandes CF, Campos KD, Pinto TF, Ramires JAF. The prognostic value of diabetes and of acute hyperglycemia is different during the in-hospital and chronic phases after myicardial infarction [Internet]. Journal of the American College of Cardiology. 2011 ; 57( 14):[citado 2024 out. 10 ] Available from: http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271027&_user=5674931&_pii=S0735109711610413&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2011-04-05&wchp=dGLbVlk-zSkWb&md5=c12e778a15601d89389d60fa28e84374/1-s2.0-S0735109711610413-main.pdf
Vancouver
Nicolau JC, Lima FG, Franken M, Serrano Junior CV, Giraldez RR, Baracioli LM, Ganem F, Fernandes CF, Campos KD, Pinto TF, Ramires JAF. The prognostic value of diabetes and of acute hyperglycemia is different during the in-hospital and chronic phases after myicardial infarction [Internet]. Journal of the American College of Cardiology. 2011 ; 57( 14):[citado 2024 out. 10 ] Available from: http://www.sciencedirect.com/science?_ob=MiamiImageURL&_cid=271027&_user=5674931&_pii=S0735109711610413&_check=y&_origin=browse&_zone=rslt_list_item&_coverDate=2011-04-05&wchp=dGLbVlk-zSkWb&md5=c12e778a15601d89389d60fa28e84374/1-s2.0-S0735109711610413-main.pdf